Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Stomatitis 2Mouth Diseases 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × FGF20 protein, human × Clear all
NCT00323518 2016-04-13

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

Celldex Therapeutics

Phase 2 Completed
390 enrolled

Mouth Diseases, Stomatitis

NCT00104065 2016-03-15

Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant

Celldex Therapeutics

Phase 2 Completed

Mouth Diseases, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡